Skip to main content

Table 1 Ongoing trials evaluating the role of sentinel node biopsy in breast cancer

From: Current status of sentinel lymph node biopsy in solid malignancies

Study[23, 24] Start date Sample size Design
Axillary Lymphatic Mapping Against Nodal Axillary Clearance (ALMANAC) 2000 1260 Randomise to: ALND or sampling vs. SN biopsy
After Mapping of the Axilla: Radiotherapy or Surgery (AMAROS) 2001 3485 If SN positive randomise to: ALND vs. RT
German Clinical Interdisciplinary Sentinel Study (KiSS) 2000 1912 If SN negative randomise to: ALND vs. no ALND
French Randomised Sentinel Node Study (Fransenod) NA* 446 SN biopsy patients randomised to peritumoural injection vs. periareolar injection
International Breast Cancer Study Group Trial (IBCSG 23-01) 2001 1960 If SN positive for micrometastases(IHC), randomise to: ALND vs. no ALND
American College of Surgeons Oncology Group (ACOSOG-Z0010) 1999 5300 IHC positive SN patients(H&E negative) observed to determine prognostic significance; bone marrow also assayed for micrometastasis to determine incidence and significance
American College of Surgeons Oncology Group (ACOSOG-Z0011) 1999 1900 If SN positive(H&E) randomise to completion ALND vs. observation
National Surgical Adjuvant Breast and Bowel Project(NSABP-B-32) 1999 4500 If SN negative randomise to: completion ALND vs. no additional axillary treatment
Royal Australasian College of Surgeons Sentinel lymph Node biopsy versus Axillary Clearance (RACS SNAC) 2001 1000 SN negative patients randomised to completion ALND vs. no additional axillary treatment
  1. ALND, Axillary lymph node dissection; SN, sentinel lymph node; RT, radiotherapy; IHC, immunohistochemical staining; H&E, haematoxylin and eosin. *Not available